PLSE

ANALYST NOTE: PLSE (Pulse Biosciences, Inc.) Date: 2026-06-13 Analyst: StoryStocks-Native Equity Research

1. Structural Readiness

Conservative Entry: $27.10 Current Price: $25.60 Extension: -5.5% vs. conservative entry Breakout Level: $27.10 (Conservative) / $27.10 (Aggressive/Pre-breakout)

Classification: FORMING

Volatility Context:

• ATR at Breakout: 6.5% (Very High) — Indicates high structural quality and potential for significant expansion upon breakout.
• Current ATR: 7.0% (Very High) — Reflects elevated daily volatility, requiring careful position sizing to withstand noise.

2. Thesis Layer

Thesis Classification: TACTICAL / SETUP-LED As of 2026-06-13, there is no named secular thesis attached to this setup. This is not a macro-driven or sector-rotation play at this specific moment. The investment case must be judged strictly on the quality of the technical setup (the Coil structure) and the underlying business fundamentals available in the evidence base. No external narrative or "story" should be invented to justify the position; the conviction rests entirely on the convergence of the forming price structure and the specific clinical/commercial milestones recorded by management.

3. Business Overview

Company: Pulse Biosciences, Inc. Industry: Healthcare / Medical Devices Business Model: Development and commercialization of Nanosecond Pulsed Field Ablation (nsPFA) technology. The company operates a dual-track model: (1) Commercializing the nPulse Vybrance System for benign skin lesions (generating early revenue) and (2) Developing the nPulse Cardiac Catheter System for atrial fibrillation (AF) via clinical trials and regulatory pathways.

Key Business Facts (As of 2026-06-13):

• Strategic Focus: In March 2026, the company executed a "2026 Realignment" to prioritize nsPFA energy for atrial fibrillation and surgical soft tissue ablation, moving away from broader diversification (Evidence E8, E10).
• Commercial Revenue: In Q1 2026, the team generated approximately $400,000 in revenue from nPulse Vybrance Systems and electrodes, demonstrating early commercial traction (Evidence E7).
• Clinical Progress (Cardiac):
• NANOPULSE-AF Study: Enrollment was completed in early Q4 2026 (accelerated from prior guidance of end-of-2026) (Evidence E1).
• Data Readout: The company presented 6- and 12-month follow-up data for the first 150 patients at the AF Symposium in February 2026. Results showed 96% procedural success at one year and early indications of market potential with procedure times of approximately 65 minutes (Evidence E14).
• Future Milestones: Management expects to use European feasibility data to finalize CE submission in H2 2026, with potential CE Mark approval in mid-2027 (Evidence E3). The IDE study enrollment is expected to be completed by the end of H1 2027 (Evidence E4).
• Other Indications: The company received FDA Breakthrough Device Designation in July 2024 for its Cardiac Surgery System (Evidence E19) and commenced the PRECISE BTN trial for thyroid procedures in September 2025 (Evidence E17).
• Accounting Treatment: In 2025, the company began capitalizing inventory for its limited market release of percutaneous electrodes, recognizing future economic benefit post-FDA approval (Evidence E11).

4. Archetype and Conviction

Archetype: Deep Value Recovery The name fits the Deep Value Recovery archetype. The company has transitioned from a pure R&D phase to a commercialization phase with a focused strategy. The "recovery" narrative is driven by the successful acceleration of clinical enrollment (completed early Q4 2026) and the validation of its core technology through robust clinical data (96% success rate). The "Deep Value" aspect is reflected in the current price action relative to the potential of a $3.0 billion addressable market in electrophysiology alone (Evidence E16), assuming the company can successfully navigate the regulatory and commercial scaling phases.

Conviction Stack:

• Thesis Strength: Moderate. The thesis is tactical and setup-led, lacking a broad secular tailwind, but the specific clinical data is strong.
• Evidence Quality: High. The evidence base is rich with specific, dated milestones (E1-E19), including precise enrollment dates, revenue figures, and clinical success rates.
• Structural Quality: High. The ATR at breakout (6.5%) and current ATR (7.0%) are in the "Very High" bucket, suggesting the stock has the volatility necessary for a significant move once the breakout occurs.
• Setup Readiness: Partial. The coil is "Forming," meaning the structure is valid, but the price has not yet confirmed the breakout. The -5.5% extension suggests the stock is in a consolidation/pullback phase within the coil.
• Rerating Potential: High. If the company successfully transitions from "clinical data" to "regulatory approval" (CE Mark mid-2027) and scales the $400k Q1 revenue, the market could re-rate the stock based on the $3B TAM.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Breakout Confirmation: A daily close above $27.10 would confirm the coil, triggering the "Confirmed-Active" state.
• Regulatory Milestones: Announcement of CE Mark approval or FDA PMA approval for the cardiac catheter.
• Revenue Acceleration: Quarterly revenue significantly exceeding the $400k Q1 2026 run rate, indicating successful commercial adoption of the Vybrance system.

What Would Invalidate the Case:

• Clinical Setbacks: Any announcement of adverse events or failure to meet endpoints in the ongoing or upcoming trials.
• Strategic Reversal: A deviation from the "2026 Realignment" focus on AF and soft tissue ablation.

Gaps in Evidence Base:

• Cash Runway: No specific evidence regarding the company's cash balance, burn rate, or financing needs as of June 2026. This is a critical gap for a clinical-stage biotech.
• Path to Profitability: While revenue is noted, there is no evidence of a timeline to profitability or gross margin expansion beyond the capitalization of inventory.
• Competitive Landscape: No specific evidence regarding competitive dynamics or market share capture rates against existing ablation technologies.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Enrollment completed early Q4 2026 ahead of schedule; 96% procedural success rate at 1 year in pivotal study; $400k Q1 2026 revenue from Vybrance system; strategic realignment to prioritize AF market. Key risks: Price below conservative entry ($27.10) with no breakout confirmation; very high ATR (7.0%) implies significant volatility and potential for whipsaw; lack of cash runway data in evidence base; regulatory timeline extends to mid-2027 for CE Mark. Sizing hint: Position size should be reduced relative to confirmed breakouts due to the "forming" state and high volatility; treat as a partial allocation pending breakout. Expected path: Management expects to finalize CE submission in H2 2026 with approval in mid-2027; revenue from Vybrance is expected to grow as commercial accounts expand; clinical data supports market potential. Expected horizon: 6 to 12 months for the setup to resolve (breakout or invalidation), with fundamental catalysts extending into 2027.